Program
nelmastobart
Also written as “Nelmastobart and Docetaxel”, “Nelmastobart in combination with TAS-102 and Bevacizumab” and “hSTC810 400 mg + Paclitaxel”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma, led by STCube.
Furthest: phase 2, since Aug 17, 20235 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| STCube | 53 open or running | phase 2since Aug 17, 2023 | Jan 25, 2022 | Aug 31, 2027phase 2 · NCT07306624 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2022First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT05231746 · 47 enrolled · United States, Korea, Republic of
- Aug 17, 2023Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06016270 · 10 enrolled · United States, South Korea
- Feb 17, 2025Phase 2 study in Colorectal NeoplasmsNCT06873763 · 52 planned · South Korea
- Dec 14, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07306624 · 62 planned · South Korea
- May 27, 2026Phase 1 study in Colonrectal Cancer (CRC)NCT07656038 · 45 planned
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07306624
- Jul 31, 2028Primary completion: phase 1 study in Colonrectal Cancer (CRC)NCT07656038
TargetBeta
BTN1A1 →read by rule
“A humanized monoclonal antibody directed against the immune checkpoint protein butyrophilin 1A1 (BTN1A1), ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656038Colonrectal Cancer (CRC) | 1 | Not yet recruiting | Jul 31, 2028 | 45 |
| NCT07306624Carcinoma, Non-Small-Cell Lung · South Korea | 2 | Recruiting | Aug 31, 2027 | 62 |
| NCT06873763Colorectal Neoplasms · South Korea | 2 | Recruiting | Dec 2025 | 52 |
| NCT06016270Extensive Stage Small Cell Lung Cancer · United States, South Korea | 2 | Terminated | Jan 23, 2025 | 10 |
| NCT05231746Colorectal Neoplasms · United States, Korea, Republic of | 1 | Completed | Feb 29, 2024 | 47 |
How it is read
Names in the registry
- “Nelmastobart and Docetaxel”, 1 entry
- “Nelmastobart in combination with TAS-102 and Bevacizumab”, 1 entry
- “hSTC810 400 mg + Paclitaxel”, 1 entry
- “hSTC810 800 mg + Paclitaxel”, 1 entry
- “Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.